MDS is a bone marrow failure disorder
MDS is a blood cancer
Learn More >
Don't Withhold Anti-Neoplastic Treatment from your Hematological Patients Infected by COVID
Season 1: Episode 2:

Don’t Withhold Anti-Neoplastic Treatment from your Hematological Patients Infected by COVID

Moshe Mittelman, MD
  • Listen on Spotify

Our host, Professor Moshe Mittelman from Tel-Aviv Sourasky Medical Center, will review 4 studies discussing if a COVID diagnosis should impact MDS treatments, therapeutic options for anemia and the use of pevonedistat with azacytidine in high-risk MDS.

  • In the first study discussed, Dr. Abi Vijenthira and colleagues performed systematic review and meta-analysis to estimate the risk of death and other important outcomes in these patients. (Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients – Blood 2020;136(25):2881-2892  (Dec))
  • Next, Dr. Pierre Fenaux and colleagues discuss how Luspatercept reduces the severity of anemia in RBC transfusion-dependent patients with LR-MDS with RS, who were refractory (or unlikely to respond to) to ESA.  (Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes – N Engl J Med 382; (2),   January 9, 2020. P.140)
  • In this study, Dr. David Henry on behalf of an international group, reported a 52-wk update of the open-label (OL) phase of a study of roxadustat in anemia in primary MDS patients that determined the starting dose of the ongoing DB study.  (Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels – Abs # 1277, Session 637, ASH 2020)
  • In our final study, Dr. Mikkael Sekeres and colleagues report preliminary results of the P-2001 trial. 120 patients with HR-MDS/CMML (IPSS-R), were randomized 1:1 to receive as 1st line therapy Aza only or the combination Aza + P. (Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML – Abs # 653, Session 637, ASH 2020; Leukemia 2021 Jan 22.)




If you have questions or feedback on this podcast, please feel free to contact us. We would love to hear from you!

Contact Us

Enjoying Our Podcasts?

If you are enjoying our podcasts and other resources, please consider becoming a Professional Member of the MDS Foundation.

Learn More About Membership
Review answers to commonly asked questions or get answers to your questions from an MDS expert